Mattia Rediti, Medical Oncologist and Bioinformatician and AIRC Postdoctoral researcher at the Metabolic reprogramming in solid tumors Lab, IFOM, shared an article on LinkedIn:
“Our work describing HER2-positive breast cancer heterogeneity (from my PhD with Christos Sotiriou at Institut Jules Bordet) is out in Nature communications.
- We identified 5 molecular subtypes in the ALTTO clinical trial (BIG against breast cancer) with external validations.
- We captured both tumor-intrinsic and microenvironment features.
- The subtypes showed prognostic value and, in neoadjuvant cohorts, differences in pCR rates.
Grateful to Christos Sotiriou for his guidance, the team at the BCTL, and all co-Authors.”
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.
Authors: Mattia Rediti, et al.
